Meiji Seika Pharma launches two-dose vial of KOSTAIVE (sa-mRNA COVID-19 vaccine) in Japan

Arcturus Therapeutics Holdings Inc.

New two-dose vial presentation of KOSTAIVE launched in Japan on September 26, 2025.
Vaccine targets SARS-CoV-2 Omicron sublineage JN.1 variant XEC.
Non-clinical studies show neutralizing antibodies against XEC, LP.8.1, XFG, NB.1.8.1 variants.
Manufacturing and marketing approval granted August 28, 2025.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.